Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Oncologica

Supplementary #1

Adverse event	N=45
Fatigue	71% (32)
Fever	18% (8)
Nausea	53% (24)
Diarrhea	82% (37)
Constipation	51% (23)
Abdominal pain	47% (21)
Paresthesia	58% (26)
Loss of muscle function	76% (34)
Muscle weakness	62% (28)
Skin symptoms	58% (26)
Dyspnea	56% (25)
Eye symptoms	76% (34)
Chest pain	62% (28)
Arthralgia/myalgia	49% (22)
Headache	53% (24)

Supplementary #1. Patient reported grade I-II adverse events. Displayed at as number of patients with given event of clinical severity at any time during treatment.

Supplementary #2



Supplementary #2. Overall survival [2A] and progression-free survival [2B] by baseline WHO PS 0, 1 and 2-3.

Supplementary #2C. WHO PS = 0 compared to WHO PS = 1-3:
HR_{OS}: 2.0 [95% CI: 1.4-3.0]; HR_{PFS}: 1.7 [95% CI: 1.2-2.4]